What Biotech Leaders Say About Working With Us

I had the privilege of working with Marisela at BioNTech, where she consistently demonstrated exceptional leadership, strategic clarity, and deep expertise in drug development from discovery through Phase I. She has a rare ability to break down complex scientific and operational challenges into clear, actionable plans, enabling teams to move forward with confidence and alignment. Marisela fosters a highly supportive and collaborative environment, combining strong empathy with a relentless commitment to excellence, even under pressure. Her ability to communicate effectively across teams and executive leadership ensures that programs remain focused, well-positioned, and strategically sound. With more than 25 years of experience in infectious diseases, she is uniquely equipped to guide early-stage drug developers in translating innovation into successful clinical entry.

Marisela Rodriguez brings over 25 years of experience in infectious diseases and a proven ability to guide early-stage drug development from discovery to Phase I trials. Her thoughtful approach to strategy and strong organizational skills enable teams to navigate the complexities of advancing therapies toward the clinic. Marisela’s expertise in stakeholder relationship management fosters collaboration across disciplines, making her a trusted partner for early-stage drug developers.

Marisela excels at providing strategic clarity, operational discipline, and cost-efficiency into early-stage drug development. I had the privilege of working with Marisela from July 2023 – January 2025 during her tenure as a Portfolio Manager of the HIV clinical programs at BioNTech. Marisela’s skills in providing strategic clarity were evident. She ensured team presentations to the C-suite were both detailed and succinct, tailored to their needs. Marisela’s in-depth scientific knowledge was a great asset during C-suite discussions, which supported the successful approval of one HIV asset for clinical development. Marisela’s ability to unite cross-functional teams and drive efficient processes makes her an invaluable leader in early-stage drug development and one whose consultancy will be highly sought after.